CSL and Alentis strike $1.55bn collab
CSL and Alentis have formed a $1.55bn collaboration to develop lixudebart, a monoclonal antibody for rare diseases. CSL will pay $355m upfront and up to $1.2bn in milestones. The drug targets AAV-RPGN, FSGS, and PSC, with CSL funding trials. Profits will be split 55% to CSL, 45% to Alentis.






